May 27, 2015

Johnson & Johnson Accepts Cardinal Health's Binding Offer to Acquire Cordis

May 28, 2015—Johnson & Johnson announced the acceptance of a March 1 binding offer from Cardinal Health to acquire its Cordis business for an approximate value of $2 billion. The transaction is expected to close in late 2015, subject to regulatory clearances and other customary closing conditions.

Johnson & Johnson remains dedicated to combating cardiovascular disease through Biosense Webster, its electrophysiology business in the medical devices segment, and its cardiovascular medicine Xarelto, the company stated in its press release.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

May 27, 2015

Johnson & Johnson Accepts Cardinal Health's Binding Offer to Acquire Cordis

Current Issue

Keep In Touch